UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Annals of oncology, 2018-04, Vol.29 (4), p.959-965

2018

Volltextzugriff (PDF)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

The New England journal of medicine, 2018-05, Vol.378 (22), p.2093-2104

2018

Volltextzugriff (PDF)

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2016-11, Vol.375 (19), p.1856-1867

2016

Volltextzugriff (PDF)

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-06, Vol.376 (25), p.2415-2426

2017

Volltextzugriff (PDF)

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

Annals of oncology, 2016-10, Vol.27, p.vi577-vi577

2016

Volltextzugriff (PDF)

Biochemical Characterization and Tissue Distribution of Human SULT2B1

Biochemical and biophysical research communications, 2001-10, Vol.288 (1), p.280-289

2001

Volltextzugriff (PDF)

A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

Annals of oncology, 2016-10, Vol.27, p.vi350-vi350

2016

Volltextzugriff (PDF)

41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S64-S65

2023

Volltextzugriff (PDF)

Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update

Annals of oncology, 2016-10, Vol.27, p.vi420-vi420

2016

Volltextzugriff (PDF)

Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

Annals of oncology, 2016-10, Vol.27, p.vi350-vi350

2016

Volltextzugriff (PDF)

LBA4_PRNivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1792-S1793

2017

Volltextzugriff (PDF)

P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S458-S458

2018

Volltextzugriff (PDF)

Genetic analysis implicates resistin in HIV lipodystrophy

AIDS (London), 2008-08, Vol.22 (13), p.1561-1568

2008

Volltextzugriff (PDF)

P3.07-012 Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2302-S2302

2017

Volltextzugriff (PDF)

A comprehensive characterization of a group IB intron and its encoded maturase reveals that protein-assisted splicing requires an almost intact intron RNA

Journal of molecular biology, 2001-05, Vol.308 (4), p.609-622

2001

Volltextzugriff (PDF)

Self-splicing activity of the mitochondrial group-I introns from Aspergillus nidulans and related introns from other species

Current genetics, 1997-12, Vol.32 (6), p.399-407

1997

Volltextzugriff (PDF)

PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study]

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.PD01-02-PD01-02

2011

Volltextzugriff (PDF)

In vitro analysis of the relationship between endonuclease and maturase activities in the bi-functional group I intron-encoded protein, I-Anil

European journal of biochemistry, 2003-04, Vol.270 (7), p.1543-1554

2003

Volltextzugriff (PDF)

In vitro analysis of the relationship between endonuclease and maturase activities in the bi‐functional group I intron‐encoded protein, I‐AniI

European journal of biochemistry, 2003-04, Vol.270 (7), p.1543-1554

2003

Volltextzugriff (PDF)

Ueber Oxydationsproducte des Dichinoyltetroxims

European journal of inorganic chemistry, 1899-01, Vol.32 (1), p.505-507

1899

Volltextzugriff (PDF)

Ueber Oxydationsproducte des Dichinoyltetroxims

Berichte der deutschen chemischen Gesellschaft, 1899-01, Vol.32 (1), p.505-507

1899

Volltextzugriff (PDF)

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2016-11, Vol.375 (19), p.1856-1867

2016

Volltextzugriff (PDF)

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1363-1372

2018

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(44)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(14)
Male
(9)
Middle Aged
(8)
Adult
(7)
Aged
(7)
Female
(7)
Oncology
(7)
Cancer Therapies
(6)
Chemotherapy
(6)
Immunotherapy
(6)
Nivolumab
(6)
Apoptosis
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Lung Cancer
(5)
B7-H1 Antigen - Metabolism
(4)
General & Internal Medicine
(4)
Lung Neoplasms - Drug Therapy
(4)
Lung Neoplasms - Pathology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

Biochemical Characterization and Tissue Distribution of Human SULT2B1

A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)

Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update

Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

LBA4_PRNivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update

P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012

Genetic analysis implicates resistin in HIV lipodystrophy

P3.07-012 Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases

A comprehensive characterization of a group IB intron and its encoded maturase reveals that protein-assisted splicing requires an almost intact intron RNA

Self-splicing activity of the mitochondrial group-I introns from Aspergillus nidulans and related introns from other species

PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study]

In vitro analysis of the relationship between endonuclease and maturase activities in the bi-functional group I intron-encoded protein, I-Anil

In vitro analysis of the relationship between endonuclease and maturase activities in the bi‐functional group I intron‐encoded protein, I‐AniI

Ueber Oxydationsproducte des Dichinoyltetroxims

Ueber Oxydationsproducte des Dichinoyltetroxims

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Suchergebnisse filtern